The Cancer Letter

The leading source for information on the issues that shape oncology since 1973

In Brief

Javier J. Zulueta joins Qure.ai as CMO

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
BYLINE
IN THIS ISSUE
DOWNLOAD PDFTABLE OF CONTENTS

Qure.ai has appointed Javier J. Zulueta, previously professor of medicine at the Icahn School of Medicine at Mount Sinai in New York and pulmonary division chief at Mount Sinai Morningside Hospital, as chief medical officer for pulmonology.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

ClinicalTrials & Tribulations

The challenge of making the move from conversational AI to autonomous scientific discovery
Advancing from level II to level III AI agents in precision medicine

Artificial intelligence is rapidly transforming biomedical research and healthcare. Large language models, foundation models, and AI agents are increasingly being deployed to assist with data interpretation, literature review, clinical decision support, and translational research. 
By Enrique Velazquez-Villarreal
Sponsored

The long life of a clinical trial
How JCO sustains landmark oncology research

In modern oncology, important insights from clinical trials often emerge years after initial publication. As new therapies extend survival and transition more patients into long-term remissions, clinicians and researchers are increasingly looking beyond initial response rates to understand durability, long-term safety, and even the possibility of a cure. 
By Journal of Clinical Oncology
In Brief

UCLA researchers awarded $3.2M NIH grant to develop AI tool for more personalized liver cancer treatment

Jason Chiang and Kyung Sung of the Department of Radiological Sciences at the David Geffen School of Medicine at UCLA and the UCLA Health Jonsson Comprehensive Cancer Center have received a $3.2 million, five-year grant from NCI to develop an artificial intelligence-enhanced imaging platform designed to improve yttrium-90 (Y90) radioembolization planning for patients with liver cancer.
Table of Contents

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login

Site license subscribers:
Log in with your IP | Register a sponsored account